• BioGaia’s third-quarter 2026 profit after tax jumped 67% to SEK 110.2 million.
• Net sales rose 23% to SEK 400.4 million.
• During the quarter, the company launched Colus, expanding its adult gut-health portfolio with a probiotic targeting colon health.
• BioGaia signed a long-term exclusive distribution agreement with Recordati for Spain and Portugal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioGaia AB published the original content used to generate this news brief via Cision (Ref. ID: 20261021:BIT:8066:0) on October 22, 2026, and is solely responsible for the information contained therein.